RAPT Therapeutics (RAPT) News Today $3.34 +0.22 (+7.05%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 24 at 11:54 AM | americanbankingnews.comRAPT Therapeutics (NASDAQ:RAPT) Receives Neutral Rating from HC WainwrightJuly 23 at 8:10 AM | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of RAPT Therapeutics in a research report on Tuesday.June 18, 2024 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Rating of "Hold" from AnalystsShares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) have been given a consensus rating of "Hold" by the thirteen analysts that are covering the stock, Marketbeat reports. Nine analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the comJune 15, 2024 | marketbeat.comOctagon Capital Advisors LP Takes $7.26 Million Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)Octagon Capital Advisors LP bought a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 292,000 shares of the company's stockJune 13, 2024 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Stake Reduced by Great Point Partners LLCGreat Point Partners LLC lowered its position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 24.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,099,753 shares of the company'sJune 12, 2024 | marketbeat.comBraidwell LP Reduces Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)Braidwell LP lessened its holdings in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 64.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 389,300 shares of the company's stock after selling 693,212 sharMay 24, 2024 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Consensus Recommendation of "Hold" by AnalystsRAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been assigned a consensus rating of "Hold" from the thirteen ratings firms that are covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation and four have issued a buy recMay 20, 2024 | seekingalpha.comRAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric OpportunityMay 14, 2024 | msn.comWolfe downgrades RAPT, but still sees "immense" upside potentialMay 14, 2024 | marketbeat.comWolfe Research Reaffirms "Peer Perform" Rating for RAPT Therapeutics (NASDAQ:RAPT)Wolfe Research reiterated a "peer perform" rating on shares of RAPT Therapeutics in a research report on Tuesday.May 12, 2024 | finance.yahoo.comHere's Why We're Watching RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn SituationMay 11, 2024 | msn.comRAPT terminates Phase II trials for lead candidate following clinical holdMay 11, 2024 | msn.comBarclays Downgrades RAPT Therapeutics (RAPT)May 10, 2024 | markets.businessinsider.comMaintaining Hold Rating on RAPT Therapeutics Amid Clinical Uncertainties and Financial OutlookMay 10, 2024 | msn.comRAPT falls for second day as Guggenheim, Barclays downgrade stockMay 10, 2024 | finance.yahoo.comRAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial OverviewMay 10, 2024 | marketbeat.comTimesSquare Capital Management LLC Invests $12.53 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)TimesSquare Capital Management LLC purchased a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 504,340 shares of the company's stoMay 10, 2024 | marketbeat.comGuggenheim Lowers RAPT Therapeutics (NASDAQ:RAPT) to NeutralGuggenheim cut RAPT Therapeutics from a "buy" rating to a "neutral" rating in a research note on Friday.May 9, 2024 | morningstar.comRAPT Therapeutics Shares Hit 52-Week Low After Trials ClosedMay 9, 2024 | finance.yahoo.comRAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon TrialsMay 9, 2024 | finance.yahoo.comWhat's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?May 9, 2024 | investorplace.comRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q1 2024May 9, 2024 | marketbeat.comTrading was temporarily halted for "RAPT" at 10:05 AM with a stated reason of "LULD pause."May 9, 2024 | globenewswire.comRAPT Therapeutics Reports First Quarter 2024 Financial ResultsApril 12, 2024 | markets.businessinsider.comHold Rating on RAPT Therapeutics Amid Promising Data and Regulatory UncertaintiesApril 11, 2024 | investing.comRAPT reports positive phase 2 cancer trial resultsApril 10, 2024 | markets.businessinsider.comMaintaining Hold Rating on RAPT Therapeutics Amidst Mixed Clinical Results and Regulatory UncertaintyApril 10, 2024 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Earns Neutral Rating from HC WainwrightHC Wainwright restated a "neutral" rating on shares of RAPT Therapeutics in a report on Wednesday.April 9, 2024 | globenewswire.comRAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer PatientsApril 9, 2024 | investorplace.com3 Biotech Stocks to Dump Before They Go to ZeroApril 4, 2024 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Moderate Buy" from AnalystsRAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve brokerages that are presently covering the company, Marketbeat reports. Six analysts have rated the stock with a hold recommendation and six have issued a buy recommendApril 1, 2024 | marketbeat.comShort Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Rises By 32.5%RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 3,300,000 shares, a growth of 32.5% from the February 29th total of 2,490,000 shares. Based on an average daily trading volume, of 1,210,000 shares, the days-to-cover ratio is presently 2.7 days.March 27, 2024 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Price Target Cut to $13.00JPMorgan Chase & Co. reduced their price target on shares of RAPT Therapeutics from $15.00 to $13.00 and set a "neutral" rating on the stock in a research report on Wednesday.March 16, 2024 | finance.yahoo.comRAPT Apr 2024 10.000 putMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTMarch 11, 2024 | markets.businessinsider.comHold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial ConcernsMarch 8, 2024 | finance.yahoo.comRAPT Oct 2024 5.000 callMarch 7, 2024 | investorplace.comRAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023March 7, 2024 | globenewswire.comRAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 5, 2024 | globenewswire.comRAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual MeetingMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPTMarch 1, 2024 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Bought by Braidwell LPBraidwell LP grew its holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 10.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,082,512 shares of the company's stock after acquiring an addiFebruary 29, 2024 | marketbeat.comFmr LLC Grows Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)Fmr LLC increased its position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 7.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,499,293 shares of the company's stock after aFebruary 26, 2024 | businesswire.comRAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsFebruary 23, 2024 | finance.yahoo.comRAPT May 2024 17.500 putFebruary 22, 2024 | msn.comUBS Downgrades RAPT Therapeutics (RAPT)February 22, 2024 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Downgraded by UBS Group to NeutralUBS Group cut shares of RAPT Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the company from $61.00 to $10.00 in a report on Thursday.February 21, 2024 | msn.comHC Wainwright & Co. Downgrades RAPT Therapeutics (RAPT)February 21, 2024 | msn.comLeerink Partners Downgrades RAPT Therapeutics (RAPT)February 21, 2024 | realmoney.thestreet.comRapt Therapeutics just downgraded at Leerink, here's why Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address We’re in a code red crisis and 99% of Americans are clueless (Ad)Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! RAPT Media Mentions By Week RAPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RAPT News Sentiment▼0.360.62▲Average Medical News Sentiment RAPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RAPT Articles This Week▼42▲RAPT Articles Average Week Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Organogenesis News Today Precigen News Today Alto Neuroscience News Today Neoleukin Therapeutics News Today Q32 Bio News Today UroGen Pharma News Today Xeris Biopharma News Today Vanda Pharmaceuticals News Today AC Immune News Today Inozyme Pharma News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RAPT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RAPT Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.